WALD

WALD

USD

Waldencast plc Class A Ordinary Share

$2.690-0.080 (-2.888%)

实时价格

Consumer Defensive
Household & Personal Products
美国

价格图表

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$2.770

最高价

$2.770

最低价

$2.555

成交量

0.00M

公司基本面

市值

346.1M

所属行业

Household & Personal Products

国家/地区

United States

交易统计

平均成交量

0.05M

交易所

NCM

货币

USD

52周价格范围

最低价 $2.31当前价 $2.690最高价 $5.46

AI分析报告

最后更新: 2025年4月24日
由AI生成数据来源: Yahoo Finance, Bloomberg, SEC

WALD (Waldencast plc Class A Ordinary Share): What's Happening and What to Watch

Stock Symbol: WALD Generate Date: 2025-04-24 08:34:18

Let's break down what's been going on with Waldencast stock lately, looking at the latest news, how the price has moved, and what some predictions are saying. The goal here is to figure out what it all might mean and what potential moves someone might consider, keeping things easy to understand.

Recent News Buzz

Two pieces of news popped up on April 22nd that are worth noting.

First off, an analyst over at Alliance Global Partners, Aaron Grey, started covering Waldencast. That's when an investment firm starts formally following a company and giving their opinion. This analyst gave Waldencast a "Buy" rating, which is generally seen as a positive sign. On top of that, they put a price target of $5 on the stock. Think of a price target as where the analyst believes the stock could trade in the future based on their research. A $5 target is quite a bit higher than where the stock has been trading recently, suggesting they see significant room for the price to climb.

The second bit of news came from Obagi Medical, one of Waldencast's brands. They announced they're launching a new product: a Retinol + PHA Refining Night Cream. For a company in the beauty and wellness space like Waldencast, new product launches are a big deal. They can potentially bring in more sales and show the company is innovating. This news feels positive because it highlights activity and potential growth in one of their key segments.

So, putting the news together, the vibe is definitely leaning positive right now. You've got an analyst giving a thumbs-up and a new product hitting the market.

Checking the Price Action

Looking back at the last few months of trading data tells an interesting story. The stock was trading in the $3.00 to $3.50 range back in January and early February. Then, it saw a pretty significant dip, falling into the $2.30s and $2.40s by early April.

But things have shifted recently. The price has started to bounce back from those lows. On April 22nd, the same day the news came out, the stock saw a nice jump, closing higher than the previous day. The last data point we have, from April 23rd, shows the stock closing around $2.84.

Comparing this to the AI predictions provided:

  • Today's Prediction: 0.00% change (suggesting stability around the last close)
  • Next Day's Prediction: +2.16%
  • The Day after next: +3.00%

The AI seems to think this recent upward move could continue, predicting further gains over the next couple of days from the current level.

What This Might Suggest & Ideas to Consider

Based on the positive news sentiment, the recent bounce in the stock price from its lows, and the AI predicting continued short-term upward movement, the situation seems to favor potential buyers right now. It looks like there's some positive momentum building.

If you were considering this stock, what might you think about?

  • Potential Entry: Given the recent bounce and the AI's short-term forecast, an entry could be considered around the current price level (near $2.84) or perhaps on any slight dip if you wanted to wait for a better price. The recommendation data even suggests potential entry points slightly higher, around $2.97 or $3.08, which aligns with the idea that the price might continue climbing.
  • Potential Exit / Managing Risk: The analyst's $5 price target is a longer-term goal, suggesting significant potential upside if things go well. For shorter-term thinking, the AI predicts gains of around 2-3% in the next couple of days. The recommendation data gives a potential "Take Profit" level at $3.09. On the flip side, managing risk is crucial. A potential stop-loss level to consider, based on the recommendation data, is $2.62. This is below recent trading ranges and could help limit potential losses if the recent positive trend doesn't hold up.

Remember, these are just ideas based on the data provided. The positive news and predictions point to potential upside, but the stock has been volatile, and past performance or predictions are never guarantees.

A Little About the Company

Just to quickly put things in context, Waldencast plc is in the beauty and wellness business. They've got two main parts: Obagi Medical, which focuses on skincare (hence the new product news), and Milk Makeup, which is more about cosmetics. They sell their stuff through different channels, including doctors, retailers, and online. Knowing this helps understand why things like analyst coverage and new product launches are key drivers for their business and potentially their stock price. It's also worth noting from the recommendation data that while revenue growth is decent, the company has a negative P/E ratio and relatively high debt, which are factors to keep in mind when looking at the bigger picture.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research or consult with a qualified financial advisor before making any investment decisions.

相关新闻

Analyst Upgrades

Alliance Global Partners Initiates Coverage On Waldencast with Buy Rating, Announces Price Target of $5

Alliance Global Partners analyst Aaron Grey initiates coverage on Waldencast with a Buy rating and announces Price Target of $5.

查看更多
Alliance Global Partners Initiates Coverage On Waldencast with Buy Rating, Announces Price Target of $5
GlobeNewswire

Obagi Medical Announces the Launch of Retinol + PHA Refining Night Cream

A Scientific Breakthrough in Skin Renewal: A Clinically Proven Dual-Action, Slow-Release, Overnight Skin Renewal Cream for a Resurfaced, Smoother, and More Even-Looking Complexion NEW YORK, April 22, 2025

查看更多
Obagi Medical Announces the Launch of Retinol + PHA Refining Night Cream

AI预测Beta

AI建议

看涨

更新于: 2025年4月28日 02:13

看跌中性看涨

64.8% 置信度

风险与交易

风险等级3/5
中风险
适合于
价值增长
交易指南

入场点

$2.63

止盈点

$3.11

止损点

$2.41

关键因素

当前价格较MA(20)高出2.5%,位于$2.61
PDI 29.1高于MDI 23.1,且ADX 28.7,表明看涨趋势
MACD -0.0167高于信号线-0.0358,表明看涨交叉

保持更新

设置价格提醒,获取AI分析更新和实时市场新闻。